NCT03616782View on ClinicalTrials.gov

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

PHASE2RecruitingINTERVENTIONAL

Enrollment

98

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Ixazomib

Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression

Trial Locations (1)

49267

RECRUITING

Kosin University Gospel Hospital, Busan

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Ho Sup Lee

OTHER